Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Endocrine 2

Conditions

Neuroendocrine Tumors 148Carcinoma, Neuroendocrine 57Thyroid Cancer, Papillary 54Pheochromocytoma 52Thyroid Neoplasms 42Paraganglioma 42Pituitary Neoplasms 39Neoplasms 32Adrenocortical Carcinoma 31Multiple Endocrine Neoplasia Type 1 29Gastro-enteropancreatic neuroendocrine tumor 29Thyroid Carcinoma, Anaplastic 24Lung Neoplasms 22Small Cell Lung Carcinoma 21Sarcoma 20Carcinoid Tumor 20Breast Neoplasms 19Neoplasm Metastasis 18Carcinoma, Non-Small-Cell Lung 18Adenoma, Islet Cell 18Melanoma 17Carcinoma, Hepatocellular 17Pancreatic Neoplasms 16Colorectal Neoplasms 16Adrenal Gland Neoplasms 16Prostatic Neoplasms 15Ovarian Neoplasms 15Neuroblastoma 15Carcinoma, Renal Cell 15Adenocarcinoma, Follicular 15

Interventions

AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroendocrine Prostate Cancer × Endocrine × 1 year × Clear all
NCT04702737 2025-09-12

DeLLpro-300

Amgen

Phase 1 Completed
41 enrolled 19 charts
EndocrineGenitourinary

Neuroendocrine Prostate Cancer

NCT07024277 2025-06-17

Study of ZG006 in Participants With Neuroendocrine Prostate Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Not yet recruiting
60 enrolled
EndocrineGenitourinary

Neuroendocrine Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡